Abstract
Acute Myeloid Leukemia (AML) is a highly heterogeneous bone marrow cancer, characterized by biochemical dysregulation that results from molecular changes in stem and progenitor cells of the hematopoietic system. These changes cause a block in cell differentiation with the accumulation of immature cells in the bone marrow and/or peripheral blood, compromising blood cell production. AML tre…